Company: CDT
Filing Date: 2025-04-25
Form Type: 8-K
Source: 0001641172-25-006224
Chunk: 0

Company: CDT Equity Inc.
Filing Date: 2025-04-25
Form: 8-K
Item: Item 4.01
Chunk 0
---
Item
4.01 Changes in Registrant’s Certifying Accountant.

On
April 24, 2025, Conduit Pharmaceuticals Inc. (the “ Company”) was notified by Marcum LLP (“ Marcum”) that Marcum
resigned as the Company’s independent registered public accounting firm. On November 1, 2024, CBIZ CPAs P. C. (“ CBIZ CPAs”)
acquired the attest business of Marcum. On April 25, 2025, with the approval of
the Audit Committee of the Company’s Board of Directors (the “ Board”), CBIZ CPAs was engaged as the Company’s
independent registered public accounting firm.

Marcum’s
audit reports on the Company’s consolidated financial statements as of and for the years ended December 31, 2024 and 2023 did not
contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting
principles, except that the audit report on the consolidated financial statements of the Company for the years ended December 31, 2024
and December 31, 2023 contained an explanatory paragraph regarding the Company stating that there was substantial doubt about the Company’s
ability to continue as a going concern.

During
the audits for the fiscal years ended December 31, 2024 and 2023 and the subsequent period through April 24, 2025, there were (i) no
disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Marcum on any
matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if
not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreements in
connection with its reports on the consolidated financial statements for the years ended December 31, 2024 and 2023, and (ii) no “reportable
events” (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions), except for the material weaknesses in
the Company’s internal control over financial reporting related to: (i) the segregation of duties is limited and heavily reliant
on interim personnel and third-party consultants to perform these activities, (ii) the Company lacks a formal process for review and
approval of significant transactions and accounts on a contemporaneous basis and there